secwatch / observer
8-K filed June 2, 2026, 4:01 PM ET ticker TYRA CIK 0001863127
other confidence high sentiment neutral materiality 0.15

Tyra Biosciences elects three Class II directors, ratifies Ernst & Young as auditor at 2026 annual meeting

Tyra Biosciences, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tyra Biosciences, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-05-28 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-05-28
Exact text from the filing
2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The appointment was ratified by the votes indicated: For Against Abstain Broker Non-Votes 53,092,820 1,316 3,246 –
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tyra Biosciences, Inc. shareholders approved Election of three Class II directors to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders. at the 2026-05-28 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-05-28
Exact text from the filing
1. The election of three directors to serve as Class II directors for a three-year term to expire at the 2029 Annual Meeting of Stockholders. The following three Class II directors were elected by the votes indicated: For Withheld Broker Non-Votes Habib J. Dable 44,242,803 476,602 8,377,977 Susan Moran, M.D., M.S.C.E. 44,529,688 189,717 8,377,977 Robert More 41,013,686 3,705,719 8,377,977
View on SEC.gov

Browse all shareholder votes →

Tyra Biosciences, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-253435
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.